NASDAQ:AVTX • US05338F3064
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AVALO THERAPEUTICS INC (AVTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-13 | BTIG | Reiterate | Buy -> Buy |
| 2026-04-09 | Wolfe Research | Initiate | Outperform |
| 2026-04-06 | Citizens | Initiate | Market Outperform |
| 2026-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-24 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-02 | Guggenheim | Initiate | Buy |
| 2026-01-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-18 | Mizuho | Initiate | Outperform |
| 2025-09-29 | BTIG | Reiterate | Buy -> Buy |
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-15 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-25 | Stifel | Initiate | Buy |
| 2025-03-25 | Jefferies | Initiate | Buy |
| 2025-03-20 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-02-28 | Piper Sandler | Initiate | Overweight |
| 2024-12-19 | BTIG | Initiate | Buy |
| 2024-12-17 | LUCID CAPITAL MARKETS | Initiate | Buy |
| 2024-10-24 | HC Wainwright & Co. | Initiate | Neutral |
| 2024-04-16 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2023-06-27 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2023-06-27 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2023-05-10 | RBC Capital | Maintains | Outperform |
| 2023-02-08 | Jefferies | Downgrade | Hold -> Underperform |
| 2022-03-03 | RBC Capital | Maintains | Outperform |
| 2022-03-03 | Jefferies | Downgrade | Buy -> Hold |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.924M -89.34% | 441K -77.08% | 59K -86.62% | -100.00% | 5.636M | 81.523M 1,346.47% | 112.04M 37.43% | 263.32M 135.02% | 491.23M 86.55% | |||
| EBITDA YoY % growth | -23.286M 37.52% | -40.702M -74.79% | -72.581M -78.32% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -23.444M 37.38% | -40.871M -74.33% | -72.925M -78.43% | -78.738M -7.97% | -110.915M -40.87% | -108.688M 2.01% | -126.232M -16.14% | -67.604M 46.44% | -61.977M 8.32% | 56.51M 191.18% | 258.1M 356.73% | |
| Operating Margin | -1,218.50% | -9,267.80% | -123,601.69% | N/A | N/A | N/A | -2,239.74% | -82.93% | -55.32% | 21.46% | 52.54% | |
| EPS YoY % growth | -488.22 54.59% | -164.27 66.35% | -6.49 96.05% | -3.51 45.98% | -3.94 -12.43% | -4.30 -9.21% | -3.45 19.91% | -1.41 59.11% | -0.30 78.65% | 1.79 693.22% | 4.42 147.71% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.10 12.11% | -0.97 49.38% | -0.84 61.74% | -0.77 32.04% | -0.90 17.84% | -0.95 1.87% | -1.00 -19.30% | -1.07 -39.47% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -19.729M -31.53% | -19.305M 0.06% | -18.971M 1.18% | -17.948M 9.09% | -22.338M -13.22% | -22.746M -17.82% | -23.154M -22.05% | -23.664M -31.84% |
All data in USD
17 analysts have analysed AVTX and the average price target is 40.46 USD. This implies a price increase of 201.94% is expected in the next year compared to the current price of 13.4.
AVALO THERAPEUTICS INC (AVTX) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of AVALO THERAPEUTICS INC (AVTX) is -1.1 USD and the consensus revenue estimate is 0 USD.
The consensus rating for AVALO THERAPEUTICS INC (AVTX) is 87.0588 / 100 . This indicates that analysts generally have a positive outlook on the stock.